Nuvectis Pharma (NVCT) Total Liabilities (2021 - 2026)
Nuvectis Pharma (NVCT) posted Total Liabilities of $11.2 million for Q1 2026, down 15.93% sequentially from $13.3 million in Q4 2025, and up 21.58% YoY from $9.2 million in Q1 2025.
Nuvectis Pharma (NVCT) Total Liabilities (2021 - 2026) Analysis & Trends
Nuvectis Pharma has reported Total Liabilities for 6 years, with the latest figure at $11.2 million in Q1 2026.
- Quarterly Total Liabilities rose 21.58% year-over-year to $11.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.2 million (up 21.58% YoY) and the FY2025 annual result came in at $13.3 million, up 49.49% from the prior year.
- Total Liabilities fell to $11.2 million in Q1 2026 per NVCT's latest filing, from $13.3 million in the prior quarter.
- Over five years, Total Liabilities peaked at $13.3 million in Q4 2025 and troughed at $2.7 million in Q2 2022.
- A 5-year average of $7.0 million and a median of $6.2 million in 2022 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2023: Total Liabilities jumped 155.73% in 2022, then advanced 12.9% in 2023.
- Over 5 years, Total Liabilities stood at $6.2 million in 2022, then advanced by 12.9% to $7.0 million in 2023, then advanced by 27.35% to $8.9 million in 2024, then jumped by 49.49% to $13.3 million in 2025, then decreased by 15.93% to $11.2 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $11.2 million, $13.3 million, and $11.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Nuvectis Pharma | 506.13 Mn | 506.13 Mn | - | 13.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.29 Mn |
| Mar 31, 2026 | 11.18 Mn |
| Dec 31, 2025 | 13.30 Mn |
| Sep 30, 2025 | 11.58 Mn |
| Jun 30, 2025 | 10.14 Mn |
| Mar 31, 2025 | 9.19 Mn |
| Dec 31, 2024 | 8.89 Mn |
| Sep 30, 2024 | 6.32 Mn |
| Jun 30, 2024 | 5.77 Mn |
| Mar 31, 2024 | 5.69 Mn |
| Dec 31, 2023 | 6.98 Mn |
| Sep 30, 2023 | 5.58 Mn |
| Jun 30, 2023 | 4.61 Mn |
| Mar 31, 2023 | 3.93 Mn |
| Dec 31, 2022 | 6.19 Mn |
| Sep 30, 2022 | 4.49 Mn |
| Jun 30, 2022 | 2.74 Mn |
| Mar 31, 2022 | 3.06 Mn |
| Dec 31, 2021 | 2.42 Mn |